Table 1.
Clinical Characteristics of Patients in the Neoadjuvant Cohort
| Characteristic | N (Total: 95) | % |
|---|---|---|
|
| ||
| Age at Diagnosis | ||
| < 50 | 56 | 58.9 |
| ≥ 50 | 39 | 41.1 |
|
| ||
| Treatment | ||
| Adriamycin − Based Therapy | 72 | 75.8 |
| Carboplatin + Paclitaxel + Herceptin | 13 | 13.7 |
| Carboplatin + Abraxane + bevacizumab | 6 | 6.3 |
| Cytoxan + Taxotere | 2 | 2.1 |
| Navelbine + Herceptin | 1 | 1.1 |
| Carboplatin + Etoposide + Taxol | 1 | 1.1 |
|
| ||
| Tumor Size | ||
| < 2 cm | 10 | 10.5 |
| 2–5 cm | 68 | 71.6 |
| ≥ 5 cm | 16 | 16.8 |
| Unknown | 1 | 1.1 |
|
| ||
| Nuclear Grade | ||
| Grade 1 | 3 | 3.2 |
| Grade 2 | 46 | 48.4 |
| Grade 3 | 43 | 45.3 |
| Unknown | 3 | 3.2 |
|
| ||
| Nodal Status | ||
| Node Positive | 48 | 50.5 |
| Node Negative | 33 | 34.7 |
| Unknown | 14 | 14.7 |